About: SARS-CoV-2 Viral and Serological Testing When College Campuses Reopen: Some Practical Considerations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 Viral and Serological Testing When College Campuses Reopen: Some Practical Considerations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	SARS-CoV-2 Viral and Serological Testing When College Campuses Reopen: Some Practical Considerations
Creator	Cheung, Chi-Ngai Handel, Andreas Fung, Chun-Hai
source	Medline; PMC
abstract	The coronavirus disease 2019 (COVID-19) pandemic prompted universities across the United States to close campuses in Spring 2020. Universities are deliberating whether, when, and how they should resume in-person instruction in Fall 2020. In this essay, we discuss some practical considerations for the use of 2 potentially useful control strategies based on testing: (1) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcriptase-polymerase chain reaction (RT-PCR) testing followed by case-patient isolation and quarantine of close contacts, and (2) serological testing followed by an “immune shield” approach, that is, low social distancing requirements for seropositive persons. The isolation of case-patients and quarantine of close contacts may be especially challenging, and perhaps prohibitively difficult, on many university campuses. The “immune shield” strategy might be hobbled by a low positive predictive value of the tests used in populations with low seroprevalence. Both strategies carry logistical, ethical, and financial implications. The main nonpharmaceutical interventions will remain methods based on social distancing (eg, capping class size) and personal protective behaviors (eg, universal facemask wearing in public space) until vaccines become available, or unless the issues discussed herein can be resolved in such a way that using mass testing as main control strategies becomes viable.
has issue date	2020-07-27(xsd:dateTime)
bibo:doi	10.1017/dmp.2020.266
bibo:pmid	32713384
has license	cc-by
sha1sum (hex)	f109768a51907a408603cb73bdbc3959d87b7b14
schema:url	https://doi.org/10.1017/dmp.2020.266
resource representing a document's title	SARS-CoV-2 Viral and Serological Testing When College Campuses Reopen: Some Practical Considerations
has PubMed Central identifier	PMC7450242
has PubMed identifier	32713384
schema:publication	Disaster medicine and public health preparedness
resource representing a document's body	covid:f109768a51907a408603cb73bdbc3959d87b7b14#body_text
is schema:about of	named entity 'hobbled' named entity 'essay' named entity 'strategies' named entity 'vaccines' named entity 'social distancing' named entity 'mass' named entity 'control' named entity 'instruction' named entity 'viable' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'quarantine' named entity 'polymerase chain reaction' named entity 'coronavirus disease 2019' named entity 'social distancing' named entity 'patient isolation' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'Medicare' named entity 'social media' named entity 'California' named entity 'COVID' named entity 'infection control' named entity 'protective antibodies' named entity 'false negative' named entity 'quarantine' named entity 'social distancing' named entity 'serological testing' named entity 'asymptomatic' named entity 'Reverse transcriptase' named entity 'Ethical issues' named entity 'COVID-19' named entity 'infection' named entity 'RT-PCR' named entity 'COVID-19 pandemic' named entity 'Chelsea, Massachusetts' named entity 'RT-PCR' named entity 'seropositive' named entity 'asymptomatic' named entity 'antibodies' named entity 'accounting' named entity 'serological testing' named entity 'seroprevalence' named entity 'reproduction number' named entity 'asymptomatic' named entity 'ethical issues' named entity 'American College Health Association' named entity 'health-care' named entity 'college campuses' named entity 'Centers for Disease Control and Prevention' named entity 'stigmatized' named entity 'asymptomatic' named entity 'False negative' named entity 'safe and effective' named entity 'SARS-CoV-2' named entity 'social distancing' named entity 'class-action' named entity 'Medicare' named entity 'meta-analysis' named entity 'reproduction number' named entity 'college campus' named entity 'laboratory tests' named entity 'SARS-CoV-2' named entity 'Fall Semester' named entity 'antibodies' named entity 'freedom of movement' named entity 'quarantine' named entity 'seroprevalence' named entity 'basic reproduction number' named entity 'quarantine' named entity 'college campuses' named entity 'SARS-CoV-2' named entity 'college campuses' named entity 'vaccines' named entity 'general population' named entity 'SARS-CoV-2' named entity 'public health' named entity '85%' named entity 'SARS-CoV-2' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software